Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Shares Issued
Ratios

Benitec Biopharma (BNTC) Gross Profit (2019 - 2024)

Benitec Biopharma (BNTC) has disclosed Gross Profit for 6 consecutive years, with -$3000.0 as the latest value for Q1 2024.

  • Quarterly Gross Profit fell 105.56% to -$3000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was -$3000.0 through Dec 2024, up 93.48% year-over-year, with the annual reading at -$108000.0 for FY2024, 244.0% down from the prior year.
  • Gross Profit hit -$3000.0 in Q1 2024 for Benitec Biopharma, down from -$1000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $54000.0 in Q1 2023 to a low of -$106000.0 in Q3 2023.
  • Historically, Gross Profit has averaged -$5266.7 across 5 years, with a median of -$1000.0 in 2023.
  • Biggest five-year swings in Gross Profit: crashed 1228.57% in 2020 and later skyrocketed 900.0% in 2022.
  • Year by year, Gross Profit stood at -$18000.0 in 2020, then skyrocketed by 238.89% to $25000.0 in 2021, then crashed by 44.0% to $14000.0 in 2022, then crashed by 107.14% to -$1000.0 in 2023, then crashed by 200.0% to -$3000.0 in 2024.
  • Business Quant data shows Gross Profit for BNTC at -$3000.0 in Q1 2024, -$1000.0 in Q4 2023, and -$106000.0 in Q3 2023.